Afficher la notice abrégée

CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies

hal.structure.identifierIowa State University [ISU]
dc.contributor.authorMOCHEL, Jonathan
hal.structure.identifierMayo Clinic [Rochester]
dc.contributor.authorEKKER, Stephen
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorJOHANNES, Chad
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorJERGENS, Albert
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorALLENSPACH, Karin
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorBOURGOIS-MOCHEL, Agnes
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorKNOUSE, Michael
hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
dc.contributor.authorBENZEKRY, Sébastien
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorWIERSON, Wesley
hal.structure.identifierNational Cancer Institute [Bethesda] [NCI-NIH]
dc.contributor.authorLEBLANC, Amy
hal.structure.identifierMayo Clinic [Rochester]
dc.contributor.authorKENDERIAN, Saad
dc.date.accessioned2024-04-04T03:01:26Z
dc.date.available2024-04-04T03:01:26Z
dc.date.issued2019-05
dc.identifier.issn1550-7416
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/192901
dc.description.abstractEnThe advent of the genome editing era brings forth the promise of adoptive cell transfer usingengineered chimeric antigen receptor (CAR) T-cells for targeted cancer therapy. CAR T-cellimmunotherapy is probably one of the most encouraging developments for the treatment ofhematological malignancies. In 2017, two CAR T-cell therapies were approved by the U. S Food andDrug Administration; one for the treatment of pediatric Acute Lymphoblastic Leukemia (ALL), the otherfor adult patients with advanced lymphomas. However, despite significant progress in the area, CART-cell therapy is still in its early days and faces significant challenges, including the complexity andcosts associated with the technology. B-cell lymphoma is the most common hematopoietic cancer indogs, with an incidence approaching 0.1% and a total of 20-100 cases per 100,000 individuals. It is awidely accepted naturally occurring model for human non-Hodgkin’s lymphoma. Current treatment iswith combination chemotherapy protocols, which prolong life for less than a year in canines and areassociated with severe dose-limiting side effects, such as gastrointestinal and bone marrow toxicity.To date, one canine study generated CAR T-cells by transfection of mRNA for CAR domainexpression. While this was shown to provide a transient anti-tumor activity, results were modest,indicating that stable, genomic integration of CAR modules is required in order to achieve lastingtherapeutic benefit. This Commentary summarizes the current state of knowledge on CAR T-cellimmunotherapy in human medicine and its potential applications in animal health, while discussingthe potential of the canine model as a translational system for immuno-oncology research.
dc.language.isoen
dc.publisherAmerican Association of Pharmaceutical Scientists
dc.subject.enImmuno-Oncology
dc.subject.enCAR T-cell
dc.subject.enLymphoma
dc.subject.enOne Health
dc.title.enCAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
dc.typeArticle de revue
dc.identifier.doi10.1208/s12248-019-0322-1
dc.subject.halSciences du Vivant [q-bio]/Cancer
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
bordeaux.journalAAPS Journal
bordeaux.volume21
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.issue3
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.peerReviewedoui
hal.identifierhal-02099159
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-02099159v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=AAPS%20Journal&rft.date=2019-05&rft.volume=21&rft.issue=3&rft.eissn=1550-7416&rft.issn=1550-7416&rft.au=MOCHEL,%20Jonathan&EKKER,%20Stephen&JOHANNES,%20Chad&JERGENS,%20Albert&ALLENSPACH,%20Karin&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée